Soluble amyloid-beta peptides potently disrupt hippocampal synaptic plasticity in the absence of cerebrovascular dysfunction in vivo.
about
Amyloid-β-Induced Dysregulation of AMPA Receptor TraffickingTargeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer's disease immunotherapeuticsMild cognitive impairment and asymptomatic Alzheimer disease subjects: equivalent β-amyloid and tau loads with divergent cognitive outcomes.Amyloid beta-protein dimers rapidly form stable synaptotoxic protofibrils.Postictal behavioural impairments are due to a severe prolonged hypoperfusion/hypoxia event that is COX-2 dependent.Cognitive and cortical plasticity deficits correlate with altered amyloid-β CSF levels in multiple sclerosis.Longitudinal testing of hippocampal plasticity reveals the onset and maintenance of endogenous human Aß-induced synaptic dysfunction in individual freely behaving pre-plaque transgenic rats: rapid reversal by anti-Aß agents.Neurovascular function in Alzheimer's disease patients and experimental models.mGlu5 receptors and cellular prion protein mediate amyloid-β-facilitated synaptic long-term depression in vivoA monoclonal antibody against synthetic Aβ dimer assemblies neutralizes brain-derived synaptic plasticity-disrupting Aβ.Soluble amyloid-β oligomers as synaptotoxins leading to cognitive impairment in Alzheimer's diseaseCritical role of soluble amyloid-β for early hippocampal hyperactivity in a mouse model of Alzheimer's disease.Arterial spin labeling imaging reveals widespread and Aβ-independent reductions in cerebral blood flow in elderly apolipoprotein epsilon-4 carriers.New ELISAs with high specificity for soluble oligomers of amyloid β-protein detect natural Aβ oligomers in human brain but not CSF.Deficits in hippocampal-dependent transfer generalization learning accompany synaptic dysfunction in a mouse model of amyloidosisNeurotransmitter receptor and time dependence of the synaptic plasticity disrupting actions of Alzheimer's disease Aβ in vivo.GluN2B subunit-containing NMDA receptor antagonists prevent Abeta-mediated synaptic plasticity disruption in vivo.Alzheimer's disease: synaptic dysfunction and Abeta.Small molecule inhibitors of amyloid β peptide aggregation as a potential therapeutic strategy for Alzheimer's disease.Does the term 'trophic' actually mean anti-amyloidogenic? The case of NGF.Nanoimaging for protein misfolding diseases.Low-n oligomers as therapeutic targets of Alzheimer's disease.Alzheimer's disease Aβ assemblies mediating rapid disruption of synaptic plasticity and memory.Soluble Aβ oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors.Amyloid-β dimers in the absence of plaque pathology impair learning and synaptic plasticity.Comparison of the Effect of Exercise on Late-Phase LTP of the Dentate Gyrus and CA1 of Alzheimer's Disease Model.Aβ dimers differ from monomers in structural propensity, aggregation paths and population of synaptotoxic assemblies.Physiological activation of mGlu5 receptors supports the ion channel function of NMDA receptors in hippocampal LTD induction in vivo.Chinese Herbal Medicine Xueshuantong Enhances Cerebral Blood Flow and Improves Neural Functions in Alzheimer's Disease Mice.
P2860
Q26748723-68BA84A6-883E-40AC-BAEC-A6C865800BCFQ26822002-A25A023C-B090-4BC1-B0E1-EA8E6F17D7F5Q33772805-7BC63CB9-20AA-40E6-8A57-DDC24F2B7191Q34330681-A0016A00-D051-4616-B49B-13337C2D78A5Q34545354-4F6DB43E-EE11-4AB2-8977-CB05E3192DABQ34661859-F1353D33-6ACA-49DF-8F85-4BD11D61C630Q34950867-C0BF6502-922C-41AD-838A-86ADB6B1B307Q35088223-3F41BD5D-7E97-4B0C-80E5-FBFA422D6C5AQ35160799-A2A38015-FFF6-469F-B998-459AADFBF4C1Q35216697-E09CFF29-2109-44E1-9E64-1821BA347548Q35643397-93160E15-EC8C-43B3-987D-5BBC9240416BQ36001449-CB512183-0C7C-4334-97FF-4371BE309265Q36692478-F46E0570-6EB7-47D7-8B70-6140D4DFA21DQ36704142-29923508-8C48-4B1B-9A87-D17705A6804DQ36717090-4DF04AF7-7737-4A04-9D3A-552439D8F236Q37350693-058F7613-95FB-46F3-91D1-688A83D888EEQ37453433-AAC392D8-E663-4EF5-8EEE-9A057C90AA3EQ37636545-9343275B-4E2A-437A-ABEE-A80953925760Q37728335-BE16786D-AA22-4A6B-9686-E3670FE141C3Q37731918-62F3945D-BF95-45B0-BCCD-CD8FB282A727Q37776219-883A61FE-06AA-495C-B123-F20EA6EAA5AFQ37829762-E2A67BED-F0E1-4482-8E1C-40126C9B1E01Q38026984-8CE44361-A14A-4F77-99EA-BEB159F274AEQ42738430-5807F685-487D-45FF-AFDB-736B0A3907BDQ46625235-A9087D40-5ADF-4AC1-A631-28DEFB3401FAQ49159731-36DDC607-5697-4549-BDEB-1EE0F3592D70Q53352144-E4114629-FC9A-4220-8C6C-1FD66425B83FQ54985266-F968CF24-37D0-4AFB-A66E-E85EA3CC4D95Q55259822-5FF6050E-DAFE-4073-AC5E-40C93D71CD10
P2860
Soluble amyloid-beta peptides potently disrupt hippocampal synaptic plasticity in the absence of cerebrovascular dysfunction in vivo.
description
2008 nî lūn-bûn
@nan
2008 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
name
Soluble amyloid-beta peptides ...... ovascular dysfunction in vivo.
@ast
Soluble amyloid-beta peptides ...... ovascular dysfunction in vivo.
@en
type
label
Soluble amyloid-beta peptides ...... ovascular dysfunction in vivo.
@ast
Soluble amyloid-beta peptides ...... ovascular dysfunction in vivo.
@en
prefLabel
Soluble amyloid-beta peptides ...... ovascular dysfunction in vivo.
@ast
Soluble amyloid-beta peptides ...... ovascular dysfunction in vivo.
@en
P356
P1433
P1476
Soluble amyloid-beta peptides ...... rovascular dysfunction in vivo
@en
P2093
Dominic M Walsh
Imelda M Smith
P304
P356
10.1093/BRAIN/AWN174
P407
P577
2008-08-04T00:00:00Z